Sugi Predict

Sugi Predict / Compounds / SCHEMBL25317289

SCHEMBL25317289

SCHEMBL25317289

Oc1ccc2c(cnn2[C@H]2C[C@H](O)C2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 8/20 0.35
▸ HTR2C P28335 3/20 0.35
▸ HTR2B P41595 3/20 0.35
▸ SYK P43405 1/20 0.34
▸ NR3C1 P04150 2/20 0.34
▸ GPR119 Q8TDV5 2/20 0.33
▸ HTR7 P34969 6/20 0.33
▸ HTR1A P08908 2/20 0.33
▸ ADRA2A P08913 2/20 0.33
▸ ADRA2B P18089 2/20 0.33
▸ ADRA2C P18825 2/20 0.33
▸ HTR1D P28221 1/20 0.33
▸ HTR4 Q13639 1/20 0.33
▸ PGR P06401 1/20 0.32
▸ KCNH2 Q12809 3/20 0.32
▸ SCD O00767 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ RXRA P19793 1/20 0.32
▸ RXRB P28702 1/20 0.32
▸ RXRG P48443 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25317290 1.00 HTR2A (0.35) HTR2AHTR2CHTR2BSYKNR3C1
SCHEMBL31389534 0.79 DDB1 (0.44) ADRA2AADRA2BADRA2CSCD
SCHEMBL25316541 0.74 NPC1 (0.35) SYKGPR119KCNH2LRRK2
SCHEMBL30506939 0.74 NPC1 (0.35) SYKGPR119KCNH2LRRK2
SCHEMBL25316544 0.74 NPC1 (0.35) SYKGPR119KCNH2LRRK2
SCHEMBL25364917 0.74 NPC1 (0.35) SYKGPR119KCNH2LRRK2
SCHEMBL20116277 0.74 KMO (0.43) HTR1ASCDLRRK2
SCHEMBL26030079 0.72 PRMT5 (0.38) SYKGPR119MEN1KMT2A
SCHEMBL26029993 0.72 PRMT5 (0.38) SYKGPR119MEN1KMT2A
SCHEMBL26030059 0.72 PRMT5 (0.38) SYKGPR119MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 — — EP disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR HTR2A 3853/4885HTR2C 3942/4885HTR2B 2756/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 HTR2A 3875/4885HTR2C 3908/4885HTR2B 2690/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR HTR2A 3853/4885HTR2C 3942/4885HTR2B 2756/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 HTR2A 3875/4885HTR2C 3908/4885HTR2B 2690/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 HTR2A 3875/4885HTR2C 3908/4885HTR2B 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.